The psychedelic drug industry continues to advance by leaps-and-bounds. But psychedelic drug stocks are well off recent highs. The sale is on!
The psychedelic drug industry continues to advance by leaps-and-bounds. But psychedelic drug stocks are well off recent highs. The sale is on!
This approval is a key step forward in the development of the company's iSTRYM digital therapeutics platform
MindMed raises CAD$19.5 million selling units at CAD$3.25.
If atai Life Sciences trades in the expected manner off its IPO, its market cap will quickly exceed the COMBINED market caps of all other psychedelic stocks.
MagicMed Industries announces an R&D partnership for the development of PsyAI(TM), a an AI-based tool to "modernize psychedelic medicine."
This potential treatment opportunity was confirmed by the company's bioinformatics platform, PsyCollage
ATAI announces closing its Series D financing round, raising $157 million.
The Company expects to have ibogaine manufactured and in use for research by Q4.
MINDCURE makes a CAD$500,000 strategic investment in ATMA Journey Centers, an Alberta-based psychedelics-assisted mental health clinic.
The completed equity investment strengthens ties between MINDCURE and ATMA
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now